tailieunhanh - Báo cáo y học: "Inhaled steroid/long-acting β2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học 'Respiratory Research cung cấp cho các bạn kiến thức về ngành y đề tài:Inhaled steroid/long-acting β2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients. | Respiratory Research BioMed Central Research Open Access Inhaled steroid long-acting p2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients Jan Lotvall1 Stephen Langley2 4 and Ashley Woodcock 3 Address Department of Internal Medicine Respiratory Medicine and Allergology Sahlgrenska Academy Goteborg University Sweden 2Medicines Evaluation Unit North West Lung Centre Wythenshawe Hospital Manchester UK 3University of Manchester Manchester UK and 4Deceased Email Jan Lotvall - Stephen Langley - woodyprof@ Ashley Woodcock - Corresponding author Published 18 August 2006 Received 29 December 2005 Respiratory Research 2006 7 110 doi 1465-9921-7-110 Accepted 18 August 2006 This article is available from http content 7 1 1 10 2006 Lotvall et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background The combination of inhaled corticosteroids ICS and long-acting p2-agonists LABA is recommended by treatment guidelines for the treatment of persistent asthma. Two such combination products salmeterol fluticasone propionate SFC Seretide GSK UK and formoterol budesonide FBC Symbicort AstraZeneca UK are commercially available. Objectives The purpose of these studies was to evaluate and compare the duration of bronchodilation of both combination products up to 24 hours after a single dose. Methods Two randomised double blind placebo-controlled crossover studies were performed. Study A was conducted in 33 asthmatic adults receiving 400-1200 mcg of budesonide or equivalent. Serial forced expiratory volume in one second FEV1 was measured over 24 hours to determine the duration of